Change in number of shares and votes in Episurf Medical AB

 

Episurf Medical AB has, in accordance with information previously announced, conducted a new issue of shares with preferential rights for the company’s shareholders and a private placement to the company’s new CFO Paul Ryfors. This has resulted in changes in the number of shares and votes in the company.

Through the new issue and the private placement, the number of A-shares has increased by 1,741,228 to 3,470,769 and the number of B-shares by 6,248,621 to 12,492,536. Consequently, the total number of shares has increased by 7,989,849 to 15,963,305 and the total number of votes by 11,472,305 to 22,904,843.
 

About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.

Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.

         For more information, please contact:
         Lena Lones, CFO Episurf Medical AB (publ)
         Phone: +46 (0) 707 18 19 75, e-mail: lena.lones@episurf.com

About Us

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.